{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Michmerhuizen AR"],"funding":["Breast Cancer Research Foundation (BCRF)","U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)","Breast Cancer Research Foundation","U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)","U.S. Department of Health & Human Services | NIH | National Cancer Institute","NCI NIH HHS","generous donation from Susan and Richard Bayer","NIGMS NIH HHS","U-M | Horace H. Rackham School of Graduate Studies, University of Michigan"],"pagination":["31"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8913671"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(1)"],"pubmed_abstract":["Endocrine therapy (ET) is an effective first-line therapy for women with estrogen receptor-positive (ER + ) breast cancers. While both ionizing radiation (RT) and ET are used for the treatment of women with ER+ breast cancer, the most effective sequencing of therapy and the effect of ET on tumor radiosensitization remains unclear. Here we sought to understand the effects of inhibiting estrogen receptor (ER) signaling in combination with RT in multiple preclinical ER+ breast cancer models. Clonogenic survival assays were performed using variable pre- and post-treatment conditions to assess radiosensitization with estradiol, estrogen deprivation, tamoxifen, fulvestrant, or AZD9496 in ER+ breast cancer cell lines. Estrogen stimulation was radioprotective (radiation enhancement ratios [rER]: 0"],"journal":["NPJ breast cancer"],"pubmed_title":["Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models."],"pmcid":["PMC8913671"],"funding_grant_id":["T32-GM007767","T32-GM113900","T32 GM113900","T32-GM007315","F31 CA254138","T32 GM007863","R21 CA267147","F31CA254138","T32 GM007315","T32 GM007767","T32-GM007863","BCRF-21-128"],"pubmed_authors":["Schwartz R","Jungles K","Liu M","Harold A","Jelley A","Nino C","Wharram B","Pierce LJ","Speers CW","Zambrana Garcia N","Azaria R","Michmerhuizen AR","Lerner LM","Pesch AM","Hayes DF","Ward C","Wilder-Romans K","Zhang A","Rae JM"],"additional_accession":[]},"is_claimable":false,"name":"Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models.","description":"Endocrine therapy (ET) is an effective first-line therapy for women with estrogen receptor-positive (ER + ) breast cancers. While both ionizing radiation (RT) and ET are used for the treatment of women with ER+ breast cancer, the most effective sequencing of therapy and the effect of ET on tumor radiosensitization remains unclear. Here we sought to understand the effects of inhibiting estrogen receptor (ER) signaling in combination with RT in multiple preclinical ER+ breast cancer models. Clonogenic survival assays were performed using variable pre- and post-treatment conditions to assess radiosensitization with estradiol, estrogen deprivation, tamoxifen, fulvestrant, or AZD9496 in ER+ breast cancer cell lines. Estrogen stimulation was radioprotective (radiation enhancement ratios [rER]: 0","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-05-31T07:07:23.652Z","creation":"2025-04-04T07:56:05.188Z"},"accession":"S-EPMC8913671","cross_references":{"pubmed":["35273179"],"doi":["10.1038/s41523-022-00397-y"]}}